Levodopa/Carbidopa(200mg/50mg) + Dopaminergic Agonists
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Impulse Control Disorder
Conditions
Impulse Control Disorder
Trial Timeline
Nov 1, 2012 → Dec 1, 2014
NCT ID
NCT01683253About Levodopa/Carbidopa(200mg/50mg) + Dopaminergic Agonists
Levodopa/Carbidopa(200mg/50mg) + Dopaminergic Agonists is a approved stage product being developed by Sandoz Group for Impulse Control Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01683253. Target conditions include Impulse Control Disorder.
What happened to similar drugs?
1 of 1 similar drugs in Impulse Control Disorder were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01683253 | Approved | Completed |
Competing Products
1 competing product in Impulse Control Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sertraline | Pfizer | Approved | 43 |